Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
Zhongshan, CN
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | -5.13% | -8.64% | -5.13% | +25.42% | +32.14% | -13.95% | -26.73% | -47.52% | -68.38% | -69.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-21.6% Q4'25: -10.3% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-81.4% Q4'25: -68.1% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.7% Q4'25: -6.7% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-0.1% Q4'25: +0.6% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.1% Q4'25: +1.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.6% ★ Q4'25: -5.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.11× Q4'25: 1.67× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
688.04M
est: 703.04M (-2.1%)
|
730.47M
est: 835.76M (-12.6%)
|
944.63M
est: 962.45M (-1.9%)
|
1.14B
est: 1.23B (-7.3%)
|
1.34B
est: 1.62B (-17.2%)
|
1.60B
est: 1.95B (-17.6%)
|
2.21B
est: 789.14M (+180.7%)
|
1.74B
est: 838.13M (+107.3%)
|
1.02B
1.02B – 1.02B
+22.3% YoY
|
1.32B
1.32B – 1.32B
+29.0% YoY
|
1.65B
1.65B – 1.65B
+25.0% YoY
|
2.08B
2.08B – 2.08B
+25.7% YoY
|
| EBITDA |
106.80M
est: 71.94M (+48.5%)
|
68.45M
est: 85.52M (-20.0%)
|
96.81M
est: 98.49M (-1.7%)
|
102.44M
est: 126.06M (-18.7%)
|
200.30M
est: 165.89M (+20.7%)
|
203.69M
est: 199.12M (+2.3%)
|
170.39M
est: 65.73M (+159.2%)
|
55.28M
est: 69.81M (-20.8%)
|
85.35M
85.35M – 85.35M
+22.3% YoY
|
110.13M
110.13M – 110.13M
+29.0% YoY
|
137.69M
137.69M – 137.69M
+25.0% YoY
|
173.03M
173.03M – 173.03M
+25.7% YoY
|
| EBIT |
90.75M
est: 49.11M (+84.8%)
|
46.80M
est: 58.39M (-19.8%)
|
74.45M
est: 67.23M (+10.7%)
|
78.20M
est: 86.06M (-9.1%)
|
136.77M
est: 113.25M (+20.8%)
|
141.12M
est: 135.93M (+3.8%)
|
119.49M
est: 41.09M (+190.8%)
|
-1.67M
est: 43.64M (-103.8%)
|
53.35M
53.35M – 53.35M
+22.3% YoY
|
68.84M
68.84M – 68.84M
+29.0% YoY
|
86.08M
86.08M – 86.08M
+25.0% YoY
|
108.16M
108.16M – 108.16M
+25.7% YoY
|
| Net Income |
80.54M
est: 135.93M (-40.7%)
|
53.87M
est: 160.51M (-66.4%)
|
70.06M
est: 90.76M (-22.8%)
|
85.07M
est: 92.79M (-8.3%)
|
114.69M
est: 122.44M (-6.3%)
|
138.53M
est: 149.27M (-7.2%)
|
95.21M
est: 148.61M (-35.9%)
|
17.29M
est: 156.78M (-89.0%)
|
94.11M
94.11M – 94.11M
-40.0% YoY
|
96.99M
96.99M – 96.99M
+3.1% YoY
|
121.62M
121.62M – 121.62M
+25.4% YoY
|
155.21M
155.21M – 155.21M
+27.6% YoY
|
| SGA |
264.25M
est: 352.50M (-25.0%)
|
333.88M
est: 419.05M (-20.3%)
|
451.87M
est: 482.57M (-6.4%)
|
570.59M
est: 617.67M (-7.6%)
|
647.75M
est: 812.81M (-20.3%)
|
790.58M
est: 975.63M (-19.0%)
|
1.09B
est: 399.08M (+174.3%)
|
893.86M
est: 423.85M (+110.9%)
|
518.20M
518.20M – 518.20M
+22.3% YoY
|
668.63M
668.63M – 668.63M
+29.0% YoY
|
835.99M
835.99M – 835.99M
+25.0% YoY
|
1.05B
1.05B – 1.05B
+25.7% YoY
|
| EPS |
0.12
est: 0.16 (-25.4%)
|
0.07
est: 0.19 (-64.2%)
|
0.09
est: 0.11 (-18.3%)
|
0.10
est: 0.11 (-8.9%)
|
0.14
est: 0.14 (-3.3%)
|
0.17
est: 0.18 (-3.7%)
|
0.11
est: 0.18 (-39.0%)
|
0.02
est: 0.19 (-89.2%)
|
0.11
0.11 – 0.11
-40.0% YoY
|
0.12
0.12 – 0.12
+3.1% YoY
|
0.15
0.15 – 0.15
+25.4% YoY
|
0.19
0.19 – 0.19
+27.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhi Tian Lai | Executive Chairman | 3M | male |
| Ying Feng Lai | Chief Executive & Executive Director | 3M | male |
| Xiao Jun Cao | Deputy GM & Executive Director | 2M | male |
| Ying Sheng Lai | Chief Financial Officer & Executive Director | 2M | male |
| Wing Yan | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3737.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
